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PNoninvasive Screening for Coronary Atherosclerosis and
Silent Ischemia in Asymptomatic Type 2 Diabetic Patients
Is it Appropriate and Cost-Effective?
George A. Beller, MD, MACC
Charlottesville, Virginia
Coronary artery disease (CAD) accounts for 65% to 80% of deaths in diabetic patients. The merits of screening
asymptomatic type 2 diabetic patients for either (A) the presence of coronary atherosclerosis by imaging of coro-
nary calcification using cardiac computed tomography or (B) silent ischemia by stress myocardial perfusion im-
aging (MPI) remain controversial. Some observers have advocated for such noninvasive screening in at least the
subset of the diabetic population who have significant clinical CAD risk factors, so that the highest risk patients
for future cardiac events can be identified and offered more aggressive intensive medical therapy or coronary
revascularization and optimum medical therapy. Computed tomography coronary calcium scanning could be the
first noninvasive screening test in these clinically high-risk diabetic patients, followed by stress MPI to detect
silent ischemia in those who exhibit high coronary calcium scores. (J Am Coll Cardiol 2007;49:1918–23)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.079c
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aonsiderable discussion and debate are ongoing regarding
he value of noninvasive screening for noncritical coronary
therosclerosis or silent ischemia secondary to flow-limiting
tenoses in asymptomatic type 2 diabetic patients. This
ontroversy about the merits of noninvasive screening for
oronary artery disease (CAD) in asymptomatic diabetic
atients has arisen for a number of reasons. Coronary artery
isease accounts for 65% to 80% of deaths (1) in diabetic
atients, and in 2007 approximately 17 million Americans
ave diabetes. By 2050, this number could increase to 48
illion (2). Women with type 2 diabetes are particularly prone
o cardiovascular disease and its complications. In one study,
he hazard ratio for cardiovascular mortality for women with
oth metabolic syndrome and diabetes was approximately 9.5,
ompared with women without diabetes or metabolic syn-
rome (3). The age-adjusted risk of CAD in diabetic
omen, compared with nondiabetic women, is 5.1, whereas
n men this value is 2.4 (4). The actual prevalence of
ignificant coronary atherosclerosis in a truly representative
opulation of type 2 diabetic patients has not been ascer-
ained. One estimate is that 20% of diabetic patients have
stablished CAD (5). In an asymptomatic and uncompli-
ated cohort of type 2 diabetic patients, 46.3% had evidence
f coronary calcification indicative of coronary atheroscle-
osis (6). In an autopsy study of diabetic patients, the
revalence of anatomic CAD was 50% to 81% (7).
rom the Cardiovascular Division, Department of Medicine, University of Virginiap
ealth System, Charlottesville, Virginia.
Manuscript received January 11, 2007; accepted January 15, 2007.Diabetic patients with inducible ischemia on stress myo-
ardial perfusion imaging, using single-photon emission
omputed tomography (SPECT), have a significantly
igher subsequent annual cardiac death or myocardial in-
arction rate than nondiabetic patients with ischemia (10%
s. 6%) (8). In this pooled analysis of studies in the
iterature, female diabetic patients with an abnormal
PECT study had an annual rate of approximately 11.5%
or cardiac death/myocardial infarction, compared with just
bove 6% for men. In one study of female diabetic patients
ith a high-risk stress SPECT perfusion scan, characterized
y a multivessel disease pattern, only 60% survived, without
nfarction, in the ensuing 3 years. For the male diabetic
atients with a high-risk scan, this value was 79% (9).
imilarly, diabetic patients with an abnormal ischemic stress
chocardiographic response have a worse prognosis than
ondiabetic patients with stress-induced ischemia (10). The
rue prevalence of silent ischemia using noninvasive stress
maging in asymptomatic type 2 diabetic patients is not
nown, but ranges from 16% to 59% have been reported
11–15), depending on the pretest clinical risk profile of the
atient groups studied. The DIAD (Detection of Ischemia
n Asymptomatic Diabetics) study (14) comprised a lower-
isk group of type 2 diabetic patients than those imaged in
he other studies. For example, diabetic patients with an
bnormal resting electrocardiogram (ECG) were not en-
olled in the DIAD study. Fifty percent of patients in the
ayo Clinic cohort were referred for preoperative risk
ssessment, and 43% had ECG Q waves while 28% had
eripheral vascular disease (12). Female diabetic patients
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May 15, 2007:1918–23 Screening for CAD in Asymptomatic Type 2 Diabetic Patientsith normal perfusion scans or normal stress echocardio-
rams still have an annual hard cardiac event rate of 3.0%
8,10). In one observational database, diabetic patients with
schemia had a better survival rate with revascularization
ather than with medical therapy (16).
Diabetic patients with coronary atherosclerosis as deter-
ined by computed tomography (CT) calcium scanning
ave a worse outcome with respect to cardiac death and
onfatal infarction than nondiabetic patients with the same
oronary artery calcium (CAC) score (17). Interestingly,
ompared with nondiabetic patients, diabetic patients with a
ero CAC score had a similar annual mortality rate of
.36%. One group found that 48% of diabetic patients had
CAC score compatible with significant CAD (18). In
symptomatic diabetic patients, the prevalence of stress-
nduced ischemia increases the higher the CAC score is on
T scanning (6). In that study, 23% of asymptomatic
iabetic patients with a CAC of 101 to 400 had a positive
tress SPECT scan. Those with CAC 400 had a 48%
revalence of silent ischemia, and this number increased to
1.4% for the asymptomatic diabetic patients with a CAC
f1,000. The greater the extent of ischemia, the worse the
linical outcome, and the CAC score was superior to
stablished risk factors for predicting silent ischemia and
ardiac events (6). The prevalence of silent ischemia for any
iven CAC score range was higher in this study than in 2
rior reports (19,20). Conversely, in the study by Anand
t al. (6), all diabetic patients with a CAC score between 0
nd 10 had normal SPECT studies and excellent prognoses.
Some thought leaders have recommended the adoption of
ecision-making algorithms that advocate noninvasive
creening for CAD in the asymptomatic diabetic popula-
ion, and some have suggested that screening at least some
ubset of the diabetic population may be clinically valuable
21–24). These ideas are supported by the high preva-
ence of CAD and high cardiovascular mortality rate in
he diabetic population, the substantial risk of future cardiac
vents in asymptomatic diabetic patients with subclinical
therosclerosis (as assessed by CT calcium scanning), the
revalence of silent ischemia in diabetic patients, and the
igher cardiac event rate with inducible ischemia for dia-
etic patients versus nondiabetic patients. Other experts,
owever, remain skeptical or cautious regarding the worth
nd cost-effectiveness of screening diabetic patients for
oronary atherosclerosis or silent ischemia (25,26). Some
bservers are open to the concept of screening asymptomatic
iabetic patients but want to see a randomized clinical trial
f screening versus no screening to establish efficacy, recog-
izing that the cost of such a trial would be enormous and
ould only be funded by a governmental agency (27).
Certainly, diabetic patients with symptoms such as
hest pain or dyspnea are presently being evaluated
ppropriately with noninvasive and/or invasive strategies,
epending upon their clinical presentation. In one com-
ined report from Cedars Sinai, Los Angeles, and the
asel groups, 51% of 151 diabetic patients with dyspneand no chest pain had objective
vidence of CAD by SPECT
riteria (13). Asymptomatic dia-
etic patients are already being
reated as CAD equivalents with
espect to guidelines for lipid
owering (low-density lipopro-
ein [LDL] cholesterol 100
g/dl). In diabetic patients with
stablished CAD, LDL choles-
erol levels should be lowered to
elow 70 mg/dl (28).
In this issue of the Journal,
iamond et al. (29) analyze the
xpected costs and benefits asso-
iated with routine screening of
symptomatic diabetic patients
or subclinical atherosclerotic disease, using myocardial
erfusion imaging. They discuss the merits of a conditional
est-treatment strategy in which scintigraphic testing is
ollowed by statin treatment in positive test responders,
ompared with an unconditional treatment strategy involv-
ng no testing, but rather treating all diabetic patients with
tatins. Their analysis shows that unconditional treatment
osts 24% less and prevents 25% more atherosclerotic events
nnually. This essay was written primarily in response to the
eview by Bax et al. (22) representing a group of physicians
rom Europe and the U.S. identified as the “Global Dia-
ogue Group for Evaluation of Cardiovascular Risk in
atients With Diabetes.” Bax et al. (22) reviewed all the
ata in the literature pertaining to screening asymptomatic
iabetic patients for silent ischemia. The evidence they cited
uggested a “potential algorithm,” summarized in Figure 1.
symptomatic diabetic patients over 40 years old, who are
Figure 1 Algorithm for Risk Assessment and Management
in Asymptomatic Type 2 Diabetic Patients
MPS  myocardial perfusion imaging.
Reprinted with permission from Bax et al. (22).
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CT  computed
tomography
ECG  electrocardiogram
LDL  low-density
lipoprotein
MPI  myocardial perfusion
imaging
SPECT  single-photon
emission computed
tomography
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Screening for CAD in Asymptomatic Type 2 Diabetic Patients May 15, 2007:1918–23lassified as moderate or high risk based on a conventional
isk evaluation, are referred to stress myocardial perfusion
maging. Those with moderate or severe perfusion abnor-
alities would undergo invasive coronary angiography.
hose with mild defects would be candidates for aggressive
isk factor modification and medical therapy, with possible
epeat testing in 2 years. Diabetic patients with normal
erfusion scans would have their risk factors modified
ccording to practice guidelines and undergo “conventional”
ollow-up. Recall that diabetic patients with normal
PECT studies, particularly women, still have an approxi-
ate 2.5% to 3.0% annual hard event rate in follow-up.
ater in their review, Bax et al. (22) then modify this
potential algorithm” in light of the previously discussed
tudy by Anand et al. (24), which used CAC scoring by CT
o identify which patients would benefit most from subse-
uent stress perfusion imaging. In this scenario, the algo-
ithm in Figure 1 would be modified to refer patients to
tress perfusion imaging only after CT calcium scanning (a
uch less expensive procedure) revealed the presence of
ignificant atherosclerosis. The cutoff CAC scores for such
riage to stress perfusion imaging is not yet clear, but could
e 100 or 400, based on the results of ongoing clinical
esearch in this area.
Diamond et al. (29) reject the screening approaches
escribed in the preceding text. Using what they call a
back-of-the-envelope” calculation, they conclude that an
lternative unconditional strategy to noninvasive test screen-
ng, which they refer to as “test no one, and treat everyone,”
ields better outcomes at lower cost. In the absence of
reatment, 280,000 events per year are expected in a target
opulation of 14 million diabetic patients (2% event rate).
sing data from randomized trials, they assume that treat-
ng everyone will reduce events by 30%—84,000 events
revented at a treatment cost of $10.1 billion annually ($720
year for statin therapy). The cost per prevented event is
120,238. Without going into the exact details of their
ethodology, the principle employed in the calculations for
he test-treatment strategy is Pareto’s rule (30), which states
hat a test like myocardial perfusion imaging will identify
pproximately 20% of the population among whom 80% of
he events will occur. By applying this principle to the
opulation of 14 million diabetic patients, only 2.8 million
re treated, which would prevent 67,200 events at a cost of
13.3 billion. The cost per prevented event is $197,917.
gain, in this strategy, only the higher-risk population with
positive scan are treated (medically, with statins, in their
odel) with a subsequent reduction in events of only 30%.
he authors’ calculations imply that the 11.2 million pa-
ients that had a negative test would not be treated. Another
ssumption in their testing strategy is that sensitivity and
pecificity of stress testing are both 80%. In actuality,
ensitivity is closer to 85% to 90%, with near 90% specificity
or gated SPECT and attenuation correction. Finally, the
uthors also go on to show that less expensive alternative
creening tests like CAC scanning do no better than the rnconditional “treat everyone” strategy. The specificity of
AC for coronary atherosclerosis is definitely higher
han 80%.
Although hypothetical and based on certain assumptions
ith which some would not agree, the essay by Diamond
t al. (29) is of great value in that it is provocative and
ighlights the limitations of our current knowledge base on
he subject of the cost-effectiveness of screening asymptom-
tic type 2 diabetic patients. On one hand we know that
ype 2 diabetic patients, especially those with metabolic
yndrome and multiple CAD risk factors, have a substan-
ially increased risk of cardiac events compared with asymp-
omatic nondiabetic patients. We know that diabetic pa-
ients with ischemia have a worse outcome than nondiabetic
atients with ischemia, with either medical therapy or
evascularization. We also know that diabetic patients with-
ut flow limiting stenoses, but with subclinical atheroscle-
osis according to CAC scanning, have a higher event rate
han nondiabetic patients with subcritical atherosclerotic
esions. On the other hand, we do not know, in a represen-
ative, unbiased, and nonselected population of type 2
iabetic patients, the true prevalence of silent ischemia or
he true prevalence of significant subclinical coronary ath-
rosclerosis, particularly the percentage of patients vulnera-
le to acute coronary events or sudden cardiac death (e.g.,
ue to plaque rupture). The DIAD study showed a rather
ow prevalence of inducible ischemia and high-risk scans in
symptomatic type 2 diabetic patients (14), whereas the
ayo Clinic- and Cedars Sinai-based studies showed a
uch higher prevalence of patients with high-risk scans
11–13).
A problem with the approach favored by Diamond et al.
29) is that, in the conditional testing strategy, patients with
negative noninvasive study presumably are not treated
ith statins. This is not realistic, since our practice guide-
ines clearly state that all asymptomatic type 2 diabetic
atients, regardless of the presence of subclinical CAD,
hould have their LDL cholesterol lowered to below 100
g/dl. To accomplish this goal, a large percentage of
atients require statin therapy. Thus, the question should
ot be whether noninvasive test screening is appropriate for
dentifying which diabetic patients should be treated with
tatins, but whether a very high-risk group of asymptomatic
iabetic patients can be identified for whom very aggressive
herapy (including LDL cholesterol lowered to70 mg/dl),
ith or without revascularization, would be beneficial and
ost-effective. Another potential limitation of their calcula-
ions is that they do not take into account the costs incurred
y the crossover of patients in the nontested unconditionally
reated group who develop symptoms or experience cardiac
vents that may have been prevented had they been initially
ested. A high percentage of such crossover patients, who
ight have already had significant coronary atherosclerosis,
ould have been detected earlier in the noninvasive testing
trategy and more aggressively managed, thereby possibly
educing the risk of future adverse cardiovascular events.
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May 15, 2007:1918–23 Screening for CAD in Asymptomatic Type 2 Diabetic Patientsownstream costs for patients with positive scans in the
esting arm are also not calculated. An unknown number of
atients with positive test results would not just be treated
ggressively with medical therapy, but would be referred for
oronary angiography. A percentage of these patients would
ubsequently undergo coronary revascularization, which in-
reases costs even more than estimated by Diamond et al.
29). Actually, upfront costs are only a small portion of the
nduced costs. Upfront costs according to Shaw and Iskan-
rian (8) are approximately 20% of the induced costs for a
rocedure.
Another question is whether the costs of screening and
revention reduce costs from further overt disease (31).
or example, if CT calcium scanning is used as the first
creening test, and patients with CAC scores of 400 are
ery aggressively managed, leading to a reduction in
ubsequent hospitalizations for acute coronary events,
hat represents a reduction in overall costs in the condi-
ional test-treatment strategy population. A problem
ith this concept is that patients with predominantly soft
laques that are prone to rupture, causing an acute
oronary event, are missed by CT scanning for coronary
alcification. One study estimated that 16% of patients
10% were diabetic patients) with negative calcium scores
ad noncalcified plaques seen on CT angiography (32).
nother issue to consider is whether revascularization is
uperior to medical therapy in asymptomatic diabetic
atients with silent ischemia, particularly those with
igh-risk SPECT scans or stress echocardiograms. If it is
ot superior, what would be the value of a conditional
est-treatment strategy? Such a strategy is predicated, in
art, on the assumption that identifying such patients
ith silent ischemia improves their outcomes because of
ore aggressive treatment strategies than are applied to
hose with normal or low-risk results. We do not have
ny data from randomized clinical trials in which asymp-
omatic type 2 diabetic patients with ischemic noninva-
ive test findings were randomized to medical therapy versus
evascularization and appropriate medical therapy to help us
esolve this issue. Perhaps such information will be forthcom-
ng when the BARI-2D (Bypass Angioplasty Revasculariza-
ion Investigation in Type 2 Diabetics) trial results are even-
ually released. We do, however, have 1 nonrandomized study
howing improved survival in asymptomatic diabetic patients
ith high-risk SPECT imaging results treated with coronary
rtery bypass grafting (33).
A compromise approach to the screening controversy
hould perhaps be entertained and then, if affordable, a
linical randomized trial performed to validate it. This
pproach involves an algorithm that confines noninvasive
est screening to a specific high-risk population of asymp-
omatic type 2 diabetic patients. First, such a population of
symptomatic type 2 diabetic patients that truly represents a
igh-risk cohort by acknowledged epidemiologic data and
esults of prospective studies needs to be characterized,
sing clinical and routine laboratory variables. For example, st may be that patients with both type 2 diabetes and
etabolic syndrome, associated with multiple CAD risk
actors, who are over the age of 40 comprise this high-risk
roup. Women with this profile may be at a higher risk for
uture events than men. Certainly, asymptomatic type 2
iabetic patients with abnormal resting ECGs or peripheral
rterial disease would fall into this high-risk category. This
linically high-risk population of patients would not only
ave the LDL target below 70 mg/dl, but would proceed to
oninvasive testing with CT calcium scanning. Those with
AC scores of 400 would go on to stress perfusion
maging. If 10% of the left ventricle showed ischemia,
hey would go on to coronary angiography and undergo
oronary revascularization, according to accepted angio-
raphic criteria. For subcritical stenoses detected by angiog-
aphy and not associated with ischemia on noninvasive
esting, fractional flow reserve measurements might be
btained to better determine the functional significance of
he demonstrated lesions. Those patients with abnormal
cans with 10% ischemia would be treated with beta-
lockers and other risk factor modification with repeat
esting in perhaps 1 or 2 years. In this hypothetical algo-
ithm, patients with normal scans would be monitored
arefully for compliance with medications and continued
isk factor modification as mentioned in the preceding text.
f a randomized study were to be performed to validate this
lgorithm combining clinical risk stratification and nonin-
asive testing, it might be designed as an equivalence trial to
dentify whether the imaging strategy can equal the “test no
ne and treat all” strategy as characterized by Diamond et al.
29). The primary outcome is death or infarction. Secondary
utcomes are quality of life (personal well-being and treat-
ent satisfaction) and total cost, including downstream
-year costs.
Eventually, we will need better imaging techniques that
an assess both plaque burden (soft and calcified) and the
xtent of vulnerable plaques. These techniques will require
olecular imaging, currently being tested in animal and
atient models. These techniques permit delineation of
laque macrophage density and inflammatory markers (e.g.,
atrix metalloproteinases), the thickness of the fibrous cap,
he extent of the lipid-laden necrotic core, fibrin deposition,
nd the presence of neovessels (34–36). If total plaque
urden and some index of “vulnerability” could be detected
oninvasively, at a reasonable cost, then this approach may
e preferable to plaque CAC imaging, which is merely
eflective of the presence of atherosclerosis. Soft plaques, as
reviously mentioned, are missed, and no information on
ulnerability to rupture is obtained.
We are in an era in which the concept of screening
symptomatic subjects is being debated. There are sound
rguments on both sides, but in the long run, the contro-
ersy can only be resolved by gathering evidence for or
gainst screening, which requires data from a randomized
linical trial. The cost of such a trial would be enormous
ince, as Diamond et al. (29) speculate in their essay, to
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Screening for CAD in Asymptomatic Type 2 Diabetic Patients May 15, 2007:1918–23rove superiority of a testing strategy over a treat-all strategy
sing their numbers and assumptions would require the
andomization of 80,000 subjects followed for 5 years. One
ay to reduce the costs of such a study is to randomize
igh-risk asymptomatic diabetic patients based on clinical
nd laboratory criteria as previously proposed, where screen-
ng might be expected to be most cost-effective. The
roblem is that we do not yet know how to select this
igh-risk asymptomatic group. In the meantime, we should
ll be cognizant that the entire type 2 diabetic population
as to be aggressively managed with prevention strategies,
ncluding lifestyle alterations such as weight reduction and
xercise, control of atherosclerosis risk factors with medica-
ions, and glucose control. Insulin resistance, a major
ontributor to inflammation, can be treated with drugs.
hen symptoms such as chest pain or exertional dyspnea
merge, stress imaging for detection of CAD and ischemia
re appropriate. We will need to wait for further data before
nowing what is appropriate with respect to testing in the
otally asymptomatic diabetic population. The essay by Dia-
ond et al. (29) impels us to proceed with future clinical
esearch in this controversial area of cardiovascular medicine.
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